Health

Prosper AI称专科诊所年漏收1080亿美元 按自身爽约率、拒付率测算缩水近半

这家获a16z投资的语音智能体供应商称,专科诊所每位医生每年漏收12.5万美元。但把报告自身的爽约率、拒付率和收款率代入其旗舰案例重算,这一数字便缩水近半;剩下的也大多只是从支付方和患者转移而来,并非新增资金。

阅读原文

In this storya16z
Richard TangRichard Tang · 2 min read
Share
诊所前台一名佩戴耳机的接待员——Prosper AI的语音智能体要接的正是这类来电
1 / 5Slide 1 of 5
Prosper AI的推介就押在前台来电上:这正是其语音智能体为专科诊所承担的工作。

语音智能体供应商Prosper AI获a16z投资,主打专科诊所市场。该公司10月13日发布研究报告称,美国皮肤科、眼科、消化科、妇产科、初级保健和骨科诊所每年漏收1080亿美元,折合每位医生约12.5万美元,分属四大收入杠杆1。投资方a16z当天就跟进造势,放大了这一数字2。可一旦把报告自带的爽约率、拒付率等数据代入其旗舰案例重算,这个头条数字便站不住脚。

套用报告自身比率,旗舰案例缩水

旗舰案例是北卡罗来纳州的皮德蒙特整形外科与皮肤科诊所(Piedmont Plastic Surgery and Dermatology):37名接诊医生,8月预约量同比增长17%,新增预约3315个;报告按美国医疗集团管理协会(MGMA)皮肤科单次就诊392美元的标准,将这批新增预约估价为130万美元2。但同一份报告又测得:平均爽约率18.8%,首次提交理赔的拒付率为10%,而患者就诊时的应付款,诊所现场只能收回39%2。

把这些比率套到新增预约上一算,真正能收进账的收入约为74万至95万美元,而非130万美元。所谓1080亿美元,只是四个最优情形的简单相加,相互之间没有任何冲抵。

来电是最大杠杆,另外三项是本就欠下的钱

$0$20,000$40,000$60,000来电与预约排班患者再激活避免拒付追回患者欠款$14,100$44,800
Data
每位医生每年
来电与预约排班$44,800
患者再激活$37,400
避免拒付$28,500
追回患者欠款$14,100
Prosper AI报告列出的四大收入杠杆(每位医生每年,单位:美元):接听来电与排满号源、再激活患者、避免拒付、追回患者欠款。资料来源:Prosper AI《增长报告》,2026年10月13日[1]。1

四大杠杆大多是本就欠下的钱

四大收入杠杆中,避免拒付、追回患者欠款、再激活流失患者这三项,针对的都是本就已欠下的钱1。主动权在诊所手里,这也是Prosper这套推介里诚实的部分:接起每一通来电、在患者就诊前核实保险权益,都是实打实的工作;而Prosper在皮德蒙特诊所的成果显示,这一能力已经上线13。

但在2027年,联邦医疗保险优势计划(Medicare Advantage)将把320万参保人转入新计划,药品计划的平均免赔额上调23%,自付上限提高9%5;美国医疗保险和医疗补助服务中心(CMS)将对约7700个诊疗代码的工作相对价值单位(wRVU)砍去2.5%,这一刀1月1日就会落在以手术操作为主的专科头上4;联邦医疗保险(Medicare)临时的2.5%支付上调也将在年底到期1。在这样的背景下,那12.5万美元中的大部分,不过是把钱从支付方和患者转移到诊所,谈不上是谁创造出来的增长。

缺口确实存在,AI至今尚未弥合

行业自身的最新数据也说明,这一缺口真实存在,却尚未填上:美国医疗集团管理协会(MGMA)最新发布的薪酬报告发现,只有46%的诊所负责人表示AI提升了接诊医生的效率4。还有几位受访者说,AI缩短了病历书写时间,但就诊量和收入并没有因此增加。

Prosper已完成由a16z领投的3000万美元A轮融资,产品已进驻100多家医疗集团6。给投资者的启示是:先拿它自己的爽约率算一遍账,给市场规模那页PPT打个折;真正值得掏钱的,是能填平收款缺口的实干者——而Prosper正在用一通接一通的预约电话证明,自己就是这样的选手。

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    OpenEvidence's prior-auth letters no better than ChatGPT's in Mayo test; $15 billion buys its distribution

    A Mayo Clinic head-to-head and a Nature Medicine study put the quality of OpenEvidence's answers on the record in one week: good enough to use, no longer uniquely good. At $15 billion, investors are paying for distribution, and distribution now has company.

    Health

    Eli Lilly's 79% ovarian cancer response rate came from a dose its Phase 3 won't use

    Lilly's headline response rate at ESMO was measured at 4 mg/kg; the Phase 3 runs 3 mg/kg, and the combination result at that dose is unpublished. A day earlier, Genmab posted a positive Phase 3 on the same payload class.

    Health

    Molina's 10-Q moves its two biggest Medicaid wins past the 2027 recovery the Street is pricing

    The 10-Q moves the Georgia and Texas wins to late 2027 or 2028 while the Street raises targets on 2027 rates; the Florida children's contract is guided to a $1.50-per-share quarterly loss and about 700 autism providers say they are unpaid. The recovery-year revenue arrives after the recovery year.

    Health

    Intuitive Surgical to pay $450 million to settle hospitals' antitrust suit; revenue per procedure falls 3-5%

    Intuitive settled the hospitals' instrument-servicing antitrust case for $450 million, then disclosed its own 3-5% per-procedure price cut for 2027. The recurring revenue that carries 84% of sales now faces cheaper instruments on two fronts, just as US procedure growth slows to 10%.

    Health

    A compounded Zepbound recall hands Eli Lilly its exhibit as a fifth of US GLP-1 users take copies

    Apothecary Pharma could not guarantee the safety of 22 lots of compounded tirzepatide. With roughly a fifth of U.S. GLP-1 users on compounded copies, the October 29 and November 4 earnings prints will price what the copycat channel costs Lilly and Novo.

    Health

    Veeva sells AI flat, and IQVIA's seven-month clock starts the test

    Veeva priced Vault AI at 10 percent of a subscription with unlimited usage, betting model costs fall faster than adoption, while IQVIA's seven-month rollout puts a clock on the standardization it needs first.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.